Company Overview
- Website
- avencell.com
- Phone
- (617) 941-7468
- Employees
- 69
- Industry
- BioTech/Drugs
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$50B
Recent News & Media
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
- Jun 30, 2025
- prnewswire.com
AvenCell Therapeutics
- Oct 23, 2024
- thepharmaletter.com
Ropes & Gray Advises AvenCell Therapeutics in $112 Million Series B Funding
- Oct 23, 2024
- ropesgray.com
AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers
- Oct 22, 2024
- endpts.com
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
- Oct 22, 2024
- prnewswire.com
US: AvenCell Therapeutics raises US$112m in Series B financing
- Oct 22, 2024
- investorsinhealthcare.com
Who is AvenCell
AvenCell is a biotechnology company headquartered in Cambridge, Massachusetts. They are a mid-sized company with 69 employees. AvenCell focuses on the development of innovative immunotherapies aimed at treating challenging cancers. Their cutting-edge research leverages a strong scientific foundation to create novel treatments for patients who lack effective options. The company distinguishes itself through its dedication to advancing immunotherapy research and its patient-centric approach. For more information, visit AvenCell's website at avencell.com.
Company Leadership
AvenCell Industry Tags
Companies Similar to AvenCell
Analyze industry trends and opportunities by examining competitors and companies comparable to AvenCell, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | Cambridge, MA | |||
| 50M | 24 | Cambridge, MA | ||
| 50M | 68 | Cambridge, MA | 2000 | |
| 50M | 7 | Boston, MA | 2006 | |
| 50M | 225 | Boston, MA | 2002 |